Regulatory Context for Dermatology

Dermatology in the United States operates within a layered regulatory environment that spans federal statutes, state licensing boards, drug approval pathways, and evolving telehealth frameworks. Understanding which authorities govern which aspects of dermatologic practice — from the prescription of biologics to the credentialing of practitioners — determines how care is structured, what qualifications providers must hold, and how patients can exercise their rights. Gaps and overlaps in this framework create meaningful variation in care access and quality standards across state lines.

Where gaps in authority exist

No single federal statute comprehensively governs the practice of dermatology as a specialty. Physician licensing, scope of practice determinations, and clinical supervision requirements remain exclusively within state jurisdiction under the Tenth Amendment, creating a 50-jurisdiction patchwork. This produces measurable disparities: the scope of practice permitted for nurse practitioners performing skin procedures, for example, differs sharply between states with full practice authority — such as Alaska and New Mexico — and states requiring physician oversight.

A second gap exists at the boundary between cosmetic and medical dermatology. Procedures classified as cosmetic, including laser resurfacing and chemical peels when performed for aesthetic purposes, often fall outside insurance reimbursement regulation under the Centers for Medicare & Medicaid Services (CMS), yet the physical risks are indistinguishable from those of covered medical procedures. The Federal Trade Commission (FTC) holds authority over advertising claims for cosmetic devices but does not regulate clinical standards for their use. The result is a regulatory space where clinical outcomes monitoring is weaker for a substantial share of dermatologic procedures. For a detailed treatment of how cosmetic and medical classifications diverge, see Cosmetic vs Medical Dermatology.

A third gap involves dermatology clinical trials. The Food and Drug Administration (FDA) governs investigational new drug (IND) applications and clinical trial conduct under 21 CFR Part 312, but post-market surveillance of dermatologic drugs — particularly topical agents used off-label — relies heavily on voluntary adverse event reporting through MedWatch rather than mandatory systematic tracking.

How the regulatory landscape has shifted

The most structurally significant shift in dermatology regulation occurred through the expansion of telehealth frameworks following the Public Health Service Act amendments and CMS waivers issued under the COVID-19 public health emergency declaration. By 2021, CMS had permanently extended certain telehealth coverage provisions beyond the emergency period under the Consolidated Appropriations Act of 2021, directly affecting teledermatology reimbursement pathways. The topic of Teledermatology in the US covers operational dimensions of this shift in detail.

Biologics regulation has also evolved substantially. The Biologics Price Competition and Innovation Act of 2009 (BPCIA), enacted as part of the Affordable Care Act, created an abbreviated pathway for biosimilar approval under FDA oversight. Dermatology is disproportionately affected because biologic drugs for psoriasis, atopic dermatitis, and related inflammatory conditions represent the fastest-growing segment of dermatologic therapeutics. By 2023, the FDA had approved biosimilars for adalimumab — a widely used biologic in dermatology — following the expiration of reference product exclusivity periods.

The 21st Century Cures Act (2016) introduced additional regulatory changes relevant to dermatology by expanding definitions of software as a medical device (SaMD), which now encompasses AI-assisted dermoscopy tools and teledermatology diagnostic platforms subject to FDA oversight under the Digital Health Center of Excellence framework.

Governing sources of authority

The primary federal authorities governing dermatology-adjacent regulation include:

  1. Food and Drug Administration (FDA) — Drug and biologic approvals, device clearance (including dermatologic lasers under 21 CFR Part 878), and clinical trial oversight.
  2. Centers for Medicare & Medicaid Services (CMS) — Reimbursement policy, coverage determinations, and Physician Quality Reporting under the Merit-based Incentive Payment System (MIPS).
  3. Federal Trade Commission (FTC) — Advertising and marketing standards for cosmetic products and devices under the FTC Act, Section 5.
  4. Department of Health and Human Services (HHS) — HIPAA Privacy and Security Rules (45 CFR Parts 160 and 164), which apply to dermatology practices as covered entities handling protected health information.
  5. State Medical Boards — Licensure, discipline, and scope of practice authority for dermatologists and supervised mid-level providers.
  6. American Board of Dermatology (ABD) — Sets certification examination standards; board certification status interacts with hospital credentialing and some payer contracts, though the ABD is a private credentialing body, not a government agency. Details on credentialing requirements appear on the Board Certification in Dermatology page.

The National Dermatology Authority homepage provides orientation to how these regulatory dimensions connect across the full scope of dermatologic care.

Federal vs state authority structure

Federal authority in dermatology is product- and payer-focused: the FDA controls what drugs and devices can enter commerce, and CMS controls what Medicare and Medicaid will pay for. Neither agency tells a licensed physician which procedures to perform or in which setting, absent fraud and abuse statutes enforced by the HHS Office of Inspector General (OIG) under the Anti-Kickback Statute (42 U.S.C. § 1320a-7b) and the Stark Law (42 U.S.C. § 1395nn).

State authority governs the clinical relationship directly. State medical practice acts define who may diagnose and treat skin conditions, whether physician assistants may perform biopsies independently, and what supervision ratios apply when a dermatologist oversees non-physician staff performing laser treatments. Forty-six states have enacted some version of the Interstate Medical Licensure Compact (IMLC), easing multi-state licensure for physicians, though full reciprocity remains conditional on individual compact membership status.

Patient Rights in Dermatology Care addresses the intersection of HIPAA, state consent laws, and informed consent standards that apply within this federal-state structure.

This bifurcated structure creates a contrast that practitioners and policymakers must navigate: federal product standards are nationally uniform, while clinical delivery standards vary by state statute, creating up to 50 distinct regulatory environments for the same clinical procedures.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)